Roivant Sciences Ltd. (ROIV)

ROIV · Health Care · United States

Roivant Sciences Ltd. (ROIV) is a company in the Health Care sector, based in United States. The stock is held in 17 ETFs we track – with its largest weight of 0.34 % in XUHL (msci-usa-health-care). Anyone holding one of these ETFs also owns a small indirect stake in Roivant Sciences.

Above-average ETF coverage: 17 of the 95 ETFs we cover hold Roivant Sciences, spread across 8 indices. That puts the stock in more ETFs than 78.1 % of the 4,334 stocks we cover.

Held in17 ETFs

Highest weight0.34 %

Indices8

SectorHealth Care

CountryUnited States

ISINBMG762791017

Data note 1

Price chart

Data note 2

Performance

Performance
Year to date	+82.4 %	1 year	+179.1 %
1 month	+9.2 %	3 months	+26.8 %
Calendar year 2025	+83.4 %

52W

Data note 3

Measured in euros, Roivant Sciences returned +85.7 % year to date and +185.6 % over one year. The gap to the dollar figures above comes from the exchange rate alone: each daily price is converted at the ECB euro reference rate for the same day.

Data note 4

Risk metrics

Max drawdown-28.6 %

Volatility p.a.39.6 %

Data note 5

Below peak-5.4 %

Beta to S&P 5001.01

Correlation to S&P 5000.28

The close on Sep 16, 2026 was 5.4 % below the highest close since Sep 3, 2024, reached on Sep 9, 2026. Over the last 252 trading days, on days when the S&P 500 rose or fell 1 %, Roivant Sciences moved on average 1.01 % in the same direction. The correlation of 0.28 shows how reliable that average is: the broad market explained only a small share of the daily moves.

Data note 6

Correlated with

The strongest co-movers on top, the most inverse below. Low or negative values improve portfolio diversification.

Correlated with
Instrument	r	−1 … +1
AERO	+0.64
RAY	+0.54
Polkadot	+0.51
SOPH	+0.50
SOLV	+0.49
QKC	+0.49
Tradeweb Markets Inc. Class A	-0.34
Brown & Brown Inc.	-0.33
Paychex Inc.	-0.33

Data note 7

Key financials

Latest reported fiscal year (FY2025, period end 2026-03-31) as filed with the SEC.

Revenue0.0 bn $

Net income-0.3 bn $

Diluted EPS-0.54 $

Net margin-3629.2 %

Return on equity-7.0 %

Equity ratio81.7 %

Revenue growth-71.6 %

Revenue and profit by fiscal year
Fiscal year	Net income	Margin
FY2023	4.3	13294.2 %
FY2024	-0.2	-592.0 %
FY2025	-0.3	-3629.2 %

Data note 8

Held in these ETFs

Held in these ETFs
ETF	Index	Weight	per €1,000 in the ETF
XUHL / XUHC	msci-usa-health-care	0.34 %	€3.40
XDWH	msci-world-health-care	0.25 %	€2.50
SPFS	msci-world-health-care	0.25 %	€2.50
XDEM	msci-world-momentum	0.06 %	€0.60
XD9U / XD9D	msci-usa	0.03 %	€0.30
SWWD	msci-world	0.02 %	€0.20
WIMI	msci-world-imi	0.02 %	€0.20
SPYY	msci-acwi	0.02 %	€0.20
EUNL	msci-world	0.02 %	€0.20
SPPW	msci-world	0.02 %	€0.20
XDWD / XDWL	msci-world	0.02 %	€0.20
IUSQ	msci-acwi	0.01 %	€0.10
SPYI / SPSA	msci-acwi-imi	0.00 %	€0.00

Data note 9

The last column turns the weight into euros: this much of €1,000 invested in one of these funds is allocated to Roivant Sciences as of the fund's latest holdings list.

How much Roivant Sciences Ltd. overlaps with other holdings in a portfolio is shown by the Portfolio X-Ray and the ETF overlap check.

Stocks with similar ETF exposure

Names that reach a portfolio through largely the same funds as Roivant Sciences — the figure counts the ETFs holding both.

Data note 10

Key figures side by side

Key figures compared with stocks of similar ETF exposure
Stock	1 year	Volatility p.a.	Net margin	Revenue growth
Roivant Sciences	+179.1 %	39.6 %	-3629.2 %	-71.6 %
Illumina	+125.6 %	45.3 %	19.6 %	-0.7 %
Revolution Medicines	+338.3 %	56.9 %	–	–
Insmed Incorporated	-15.3 %	54.9 %	-210.5 %	+66.7 %
Medline	–	45.7 %	4069.4 %	+11.5 %
Natera	+97.3 %	47.0 %	-9.0 %	+35.9 %
Neurocrine Biosciences	+6.1 %	36.8 %	16.7 %	+21.4 %
United Therapeutics Corporation	+25.3 %	40.8 %	41.9 %	+10.6 %
Royalty Pharma Plc	+65.1 %	23.5 %	32.4 %	+5.1 %

Return and volatility from our daily closing prices in US dollars; margin and growth from the latest SEC annual filing. Fiscal years do not all end on the same date.